Market closed·Syncing…
Market closed · Close · 18 Nov

Bliss GVS Pharma Limited BLISSGVSshare price and chart

Bliss GVS Pharma closed at ₹680.35 on 18 November 2026, up 3.66% on the day. The 52-week range is ₹140.80 to ₹739.90.

₹680.35The price one share last traded at, in rupees.+3.66% · ₹24.02
52-wk low ₹14190% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹740

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on BLISSGVS

Real prices, every charge counted. Pick one or write your own.
What Bliss GVS Pharma Limited does
A short, human-reviewed summary of the business, written from public sources. Background, not analysis, and not updated intraday.
business summary

Bliss GVS Pharma makes medicines: more than 150 brands across over 50 therapeutic segments and 16 dosage forms, from six manufacturing facilities. It earned Rs 9,271 million in revenue from operations and spent Rs 189 million on research and development in 2025-26.

1
1Sector

Pharmaceuticals & Biotechnology

2
2What it sells

Pharmaceutical brands and formulations

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 18 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
57.1Neutral
0 oversold3070overbought 100
vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+2.2%vs 200 DMAHow far today's close is above or below the average closing price of the last 200 trading days, about ten months. It is the most watched line for the long-term trend.+55.4%1 monthHow much the share price has changed over the period.+8.5%3 monthsHow much the share price has changed over the period.+24.5%1 yearHow much the share price has changed over the period.+323.4%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.46.2%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Books to 30 Sept 2026
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹7,230 Cr18 NovP/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.44.7xlast 4 quarters, to Sept 2026Return on equityHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.11.6%full year FY26Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.5.60xbooks of Sept 2026Return on capitalHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.16.8%full year FY26EV / EBITDAWhat it would cost to buy the whole company, against the cash profit its business makes in a year. It is a P/E that ignores how the company is financed.30.6xDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.22%last 12 monthsDebt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.00xbooks of Sept 2026FCF marginOf every ₹100 of sales, how much cash was left after running the business and paying for new assets.8.8%year to Mar 2026

Against its sectorWhere this company ranks among similar companies on each measure.

Pharmaceuticals · 141 peers · medians
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.44.7vs 32.7 median
Cheapest: WALPAR 7.92Priciest: COHANCE 507.11
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.15.5%vs 10.14% median
Lowest: MEDIORG -86.72%Highest: SHUKRAPHAR 38.89%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.28.22%vs 20.87% median
Lowest: NECLIFE -99.78%Highest: SHUKRAPHAR 652.15%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 29 Oct 2026), sales rose 28.2% from a year earlier to ₹313 cr and profit rose 86.6% to ₹53.3 cr.

Going well
  • Sales grew 3 years running (₹710 cr in FY23 to ₹927 cr in FY26).
  • Profit grew 3 years running (₹73.9 cr in FY23 to ₹135 cr in FY26).
  • Debt to equity fell 3 years running (0.11 to 0.00).
  • Cash from operations was at least the reported profit in each of FY24, FY25, FY26.
  • Promoter holding rose 15.2 points over 8 quarters (34.82% to 50.07%).
Worth watching
  • Promoters had pledged 95.8% of their shares at the end of September 2026, 47.95% of all shares.
Also changed
  • Foreign institutions cut their holding by 7.6 points over 5 quarters (12.65% to 5.03%).
  • Domestic institutions raised their holding by 3.1 points over 5 quarters (6.54% to 9.62%).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Share price reaction to resultsWhat the share price did around each recent quarterly result.

Over the last 19 results, the share rose on 8 and fell on 11, and moved by 3% or more on 12.

+19%
-19%
Q1 FY23Q1 FY24Q1 FY25Q1 FY26Q2 FY27

Q2 FY27: results filed 29 Oct 2026. The share went from its close on 28 Oct 2026 to its close on 30 Oct 2026 -0.15%.

Dividend historyCash the company has paid per share, year by year.

₹220 / year
Paid 11 of 11 yrs
on ₹1 lakh at today's price · 0.22% yield · ₹1.5/share
What each year paid, on ₹1 lakh
88
147
147
73
73
73
73
73
73
220
17
18
19
20
21
22
23
24
25
26*
* 2026 so far - more may still be declared this year

2026 has paid ₹1.50 per share, about ₹220 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.

What it has returnedThe yearly growth rate in the share price over each period, as if it had grown smoothly.

Price only, before dividends
+17.8%a year, over 10 years
1 yr
+314.0%
3 yr
+72.4%
5 yr
+45.8%
10 yr
+17.8%

Held for 10 years this compounded at +17.8% a year. The last twelve months were up +314.0%. Price only, before dividends.

Shareholding patternThe share of the company held by its promoters, by foreign and domestic institutions, and by the public, quarter by quarter.

Who owns it
50.07%promoter holding, as of 2026-09-30+16.9 pts since 2021
Promoter share since listing
2021-0950.07% now, drawn to its own range2026-09
Who owns it todayas of Sep 26
50.1%
35.3%
Promoter50.1%Foreign (FII)5.0%Domestic (DII)9.6%Public & others35.3%
Who is buying, who is leavingJun 25 to Sep 26
Promoter50.1%+14.6 pts
Foreign (FII)5.0%-7.6 pts
Domestic (DII)9.6%+3.1 pts

Each line is that holder's share of all shares over the last 6 quarters, drawn to its own scale - the printed change is the size of the move. Mutual funds and insurers sit inside the domestic figure; hover the bar above for that split.

The promoter/promoter-group stake as a percentage of total shares, each quarter since listing. A rising line means promoters are adding to their stake; a falling one often means dilution, pledge-driven sales, or stake sales to new investors.

Promoter pledgeThe share of promoters' holdings given to lenders as security for a loan.95.77%of promoter shares, as at 2026-09-30

Insider tradesPurchases and sales of the company's own shares by promoters, directors and senior staff.

Last 18 months
Buy
Mr. Gagan Harsh Sharma
Promoters · 23-Dec-2025 16:30
2,123 sh
₹3.0 L
Buy
Mr. Gagan Harsh Sharma
Promoters · 18-Dec-2025 19:19
10,000 sh
₹14.4 L
Buy
Mr. Gagan Harsh Sharma
Promoters · 18-Dec-2025 19:19
5,000 sh
₹7.1 L
Buy
Gagan Harsh Sharma
Promoters · 01-Jul-2025 17:16
2,666 sh
₹4.2 L
Buy
Gagan Harsh Sharma
Promoters · 01-Jul-2025 17:16
7,500 sh
₹11.2 L
Buy
Gagan Harsh Sharma
Promoters · 01-Jul-2025 17:16
24,819 sh
₹36.9 L
Buy
Mr. Gagan Harsh Sharma
Promoters · 26-Jun-2025 16:48
26,056 sh
₹38.9 L
Buy
Mr. Gagan Harsh Sharma
Promoters · 26-Jun-2025 16:48
6,762 sh
₹9.4 L
Buy
Mr. Gagan Harsh Sharma
Promoters · 12-Jun-2025 16:37
1,970 sh
₹2.7 L
Buy
Mr. Gagan Harsh Sharma
Promoters · 12-Jun-2025 16:37
46,657 sh
₹63.8 L
Buy
Mr. Gagan Harsh Sharma
Promoters · 26-May-2025 16:17
4,707 sh
₹5.7 L

Recent announcementsThe company's own filings to the exchange in the last six months: results, board meetings, investor calls and more, each with its source document.

Last 6 months
Shareholders meeting17-Nov-2026

Bliss GVS Pharma Limited has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding voting results.

General Updates06-Nov-2026

Bliss GVS Pharma Limited has informed the Exchange regarding Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ( SEBI Listing Regulations )

Updates04-Nov-2026

Bliss GVS Pharma Limited has informed the Exchange regarding 'Intimation under Regulations 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Grant of Marketing Authorisation from MHRA, UK for Mesalazine 1g Suppositories'.

Copy of Newspaper Publication02-Nov-2026

Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication of Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026

General Updates29-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange about the outcome of Nomination and Remuneration Committee meeting held today i.e. on October 29, 2026, the members has granted 2,95,000 stock options under Bliss GVS Pharma Limited - Employee Stock Option Plan 2019.

Outcome of Board Meeting29-Oct-2026

Bliss GVS Pharma Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.

Copy of Newspaper Publication29-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the Postal Ballot Notice dated October 01, 2026.

Shareholders meeting28-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange regarding Notice of Postal Ballot dated October 01, 2026 ("Notice") alongwith the Explanatory Statement for seeking approval of the members of the Company by way of remote e-voting to transact the Special Business as set out in the Notice

Copy of Newspaper Publication16-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication regarding the Postal Ballot Notice.

Shareholders meeting15-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange regarding the Postal Ballot Notice dated September 28, 2026 ("Notice") alongwith the Explanatory Statement for seeking approval of the members of the Company by way of remote e-voting to transact the Special businesses as set out in the Notice

ESOP/ESOS/ESPS15-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange regarding Allotment of 53500 Shares.

Updates14-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange regarding 'Disclosure Submitted to Stock Exchanges on September 28, 2026 under Regulation 31A(10) of the SEBI Listing Regulations in relation to re-classification from the promoter and promoter group category to the public category. '.

Copy of Newspaper Publication14-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange about Copy of Newspaper Publication

Certificate under SEBI (Depositories and Participants) Regulations, 201806-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange about a Certificate under Regulation 74(5) SEBI (Depositories and Participants) Regulations, 2018

Outcome of Board Meeting01-Oct-2026

Bliss GVS Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on October 01, 2026.

Backtest idea · BLISSGVSMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on BLISSGVS
Backtest idea · BLISSGVSLower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on BLISSGVS
Backtest idea · BLISSGVSSupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on BLISSGVS
Your own ideaWrite a rule for BLISSGVS in plain English“Buy BLISSGVS when …”
Start writing
Buy the dip on BLISSGVSBuy when RSI(14) drops below 30
52-week high breakout on BLISSGVSBuy when closes at a 52-week high
Golden cross on BLISSGVSBuy when 50-day EMA crosses above 200-day
Stochastic oversold on BLISSGVSBuy when stochastic %K drops below 20
Pullback in an uptrend on BLISSGVSBuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹7,230 cr
Larger than 65% of 141 peers
sector middle ₹2,247 cr
P/EHow many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.
44.7x
Higher than 69% of 118 peers
sector middle 32.7x
Price to bookThe share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.
5.6x
Higher than 77% of 125 peers
sector middle 3.6x
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.
11.6%
Around the middle of 109 peers
sector middle 12.4%
FY23 8.1%FY26 11.6%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.
16.8%
Higher than 63% of 124 peers
sector middle 14.9%
FY23 11.5%FY26 16.8%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.
0.00
Under 0.01
sector middle 0.19
FY23 0.11FY26 0.00
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.2%
Higher than 60% of 141 peers
sector middle 0.1%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+28.2%
Higher than 62% of 130 peers
sector middle +20.9%
FY24 8.4%FY26 14.5%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY23FY24FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.16.4%FY26Profit YoYHow much net profit grew in the latest quarter against the same quarter a year earlier.+86.6%latest quarterSalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹927 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹135 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹14.5 as profit. Other income added ₹9.2.

Where it wentPer ₹100 of sales
Running costs₹83.6Depreciation₹3.6Interest₹1.3Tax₹5.9Profit₹14.5
Profit per ₹100, year by year
FY23FY26

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales+9.3%-+28.2%
Profit+22.2%-+86.6%
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Cash flowProfit is an accounting figure. Cash flow shows the money that really moved: in from the business, out on investments, and to or from lenders and shareholders.

Where the cash went

In FY26 cash rose by ₹11 Cr, after ₹57 Cr spent on plant and equipment.

FY26Cash in or out
Running the business+₹139 Cr
Investing-₹38 Cr
Lenders and shareholders-₹89 Cr
Net change in cash+₹11 Cr
Operating cash per ₹100 of profit
₹45FY23₹187FY24₹117FY25₹103FY26
₹100 or more means the reported profit arrived as cash.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY23FY24FY25FY26
Sales growthSales in this financial year against the previous one.·8.4%5.1%14.5%
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.13.7%19.6%15.6%16.4%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.10.4%10.6%11.2%14.5%
ROEHow much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.8.1%8.5%8.6%11.6%
ROCEHow much operating profit the company made on all the money in the business, whether it came from owners or lenders.11.5%11.8%11.9%16.8%
Debt to equityBorrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.0.11x0.09x0.07x0.00x
Interest coverHow many times the company's profit before interest could pay its interest bill.10.6x17.9x16.5x16.8x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · BLISSGVSStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on BLISSGVS
Backtest idea · BLISSGVSPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on BLISSGVS
Backtest idea · BLISSGVSBuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on BLISSGVS
Backtest idea · BLISSGVS52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on BLISSGVS
Backtest idea · BLISSGVSGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on BLISSGVS
MACD momentum on BLISSGVSBuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on BLISSGVSBuy when closes below the lower Bollinger band
Supertrend rider on BLISSGVSBuy when supertrend turns up
Buy the dip on BLISSGVSBuy when RSI(14) drops below 30
52-week high breakout on BLISSGVSBuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Pharmaceuticals
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.49 L cr41.0x5.0x14.7%19.1%0.0317.8%+11.9%0.85%
DIVISLAB
Divi's Laboratories Limited
2.93 L cr87.2x16.3x16.2%21.5%0.0027.6%+35.4%0.27%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.75 L cr77.9x9.6x17.0%15.2%0.7612.1%+50.8%0.82%
LAURUSLABS
Laurus Labs Limited
1.25 L cr93.6x20.7x17.7%17.9%0.4017.0%+33.4%0.09%
ZYDUSLIFE
Zydus Lifesciences Limited
1.20 L cr28.9x4.3x18.3%19.9%0.4414.1%+29.2%0.08%
DRREDDY
Dr. Reddy's Laboratories Limited
1.17 L cr41.6x3.0x11.5%13.9%0.158.3%-1.5%0.57%
CIPLA
Cipla Limited
1.14 L cr39.5x3.2x11.7%16.0%0.0110.1%-2.4%0.92%
MANKIND
Mankind Pharma Limited
1.08 L cr48.3x6.2x12.4%12.9%0.3014.7%+17.3%0.00%
AUROPHARMA
Aurobindo Pharma Limited
1.03 L cr26.1x2.6x9.9%12.8%0.2110.8%+23.9%0.39%
LUPIN
Lupin Limited
90,173 cr17.3x3.8x26.9%28.8%0.2317.0%+11.1%0.91%
GLENMARK
Glenmark Pharmaceuticals Limited
74,679 cr51.5x6.7x14.1%20.4%0.089.2%-31.3%0.09%
ALKEM
Alkem Laboratories Limited
62,443 cr30.2x4.2x17.6%20.6%0.1213.4%+13.8%1.01%
BIOCON
Biocon Limited
58,987 cr215.4x1.7x1.1%3.0%0.411.9%+2.2%0.14%
ABBOTINDIA
Abbott India Limited
54,122 cr32.7x----23.0%+11.0%2.58%
GLAND
Gland Pharma Limited
53,307 cr43.1x5.0x10.5%15.0%0.0217.5%+23.3%0.62%
IPCALAB
IPCA Laboratories Limited
47,039 cr33.5x5.4x13.2%16.6%0.0614.2%+13.8%0.32%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
44,693 cr39.5x23.8x48.9%66.5%0.0027.6%+20.8%2.16%
EMCURE
Emcure Pharmaceuticals Limited
44,294 cr40.5x8.3x19.6%24.8%0.2710.7%+24.3%0.15%
AJANTPHARM
Ajanta Pharma Limited
40,909 cr32.4x8.4x25.4%32.7%0.0220.3%+32.5%0.98%
SAILIFE
Sai Life Sciences Limited
37,978 cr100.5x14.1x15.1%20.9%0.1715.9%+22.5%0.00%
WOCKPHARMA
Wockhardt Limited
32,931 cr80.3x6.4x4.0%6.5%0.3910.8%+23.9%0.00%
ACUTAAS
Acutaas Chemicals Limited
32,677 cr74.4x17.6x23.5%31.7%0.0027.5%+42.7%0.06%
PPLPHARMA
Piramal Pharma Limited
31,813 cr-3.9x-4.0%0.8%0.69-2.1%+28.1%0.00%
NEULANDLAB
Neuland Laboratories Limited
27,527 cr60.8x13.6x21.4%27.5%0.1719.6%-12.6%0.16%
RUBICON
Rubicon Research Limited
27,450 cr84.1x19.4x19.1%23.4%0.2815.5%+39.9%0.09%
APLLTD
Alembic Pharmaceuticals Limited
20,528 cr24.3x3.5x12.4%11.7%0.259.9%+36.3%1.15%
GRANULES
Granules India Limited
19,762 cr27.6x3.0x13.5%15.7%0.0912.1%+20.3%0.22%
ERIS
Eris Lifesciences Limited
18,530 cr26.0x4.5x18.1%13.9%0.5821.6%+12.6%0.54%
ONESOURCE
Onesource Specialty Pharma Limited
18,189 cr-3.1x-1.3%0.4%0.25-0.1%+37.4%0.00%
SHILPAMED
Shilpa Medicare Limited
17,902 cr53.6x6.5x9.8%11.4%0.2418.1%+43.0%0.07%
ALIVUS
Alivus Life Sciences Limited
17,737 cr26.5x4.9x18.4%24.6%0.0024.9%+16.0%0.35%
PFIZER
Pfizer Limited
17,575 cr20.4x4.0x17.2%23.4%0.0032.4%+13.2%1.95%
COHANCE
Cohance Lifesciences Limited
17,462 cr507.1x4.5x5.1%8.0%0.06-0.3%-14.2%0.00%
NATCOPHARM
Natco Pharma Limited
16,098 cr17.7x1.6x16.9%17.1%0.1126.9%-29.0%0.70%
CAPLIPOINT
Caplin Point Laboratories Limited
15,851 cr23.0x4.1x19.9%24.7%0.0029.4%+17.9%0.38%
ASTRAZEN
AstraZeneca Pharma India Limited
15,109 cr85.0x17.2x22.8%31.2%0.006.8%+30.4%0.60%
JUBLPHARMA
Jubilant Pharmova Limited
14,870 cr56.2x2.1x6.0%8.7%0.542.9%+20.5%0.54%
CORONA
CORONA Remedies Limited
13,799 cr66.7x17.1x24.8%27.8%0.1213.3%+22.2%0.44%
MARKSANS
Marksans Pharma Limited
13,349 cr23.8x4.0x25.4%35.1%0.0116.7%+30.5%0.31%
BLISSGVS
Bliss GVS Pharma Limited
7,230 cr44.7x5.6x11.6%16.8%0.0015.5%+28.2%0.22%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
+8.2
+20.0
+1.7
+28.4
+53.7
+26.9
-13.7
+32.5
+12.6
-6.8
+2.8
·
+307.3%
11m
2025
-9.2
-16.8
-5.4
+0.9
+10.2
+20.6
+11.6
-11.7
-2.1
+2.9
+5.8
-1.6
-0.8%
2024
-9.9
+12.6
-10.8
+9.5
-16.8
-1.3
+20.2
+2.7
+5.0
-6.1
+30.9
+1.8
+32.1%
2023
+7.9
+1.9
-10.7
+7.6
-5.0
+10.3
+24.2
-2.8
-8.0
-5.7
+67.4
-11.5
+72.2%
2022
-8.2
-23.7
+6.2
+4.5
+1.1
-10.4
+6.2
+0.3
-1.0
-1.8
-4.4
+0.3
-30.2%
2021
-9.0
-5.1
-43.6
+2.8
+6.3
-1.0
+1.1
+3.3
-1.4
+0.9
-11.1
+5.3
-48.7%
2020
-5.8
-30.0
+1.4
-2.8
-4.3
+3.5
+10.7
+33.6
+18.7
+0.1
+0.2
+18.4
+34.1%
2019
-5.3
+13.5
+1.2
-6.6
-1.5
-6.6
-4.3
-27.7
-3.6
+32.7
+5.2
+4.8
-8.7%
2018
-3.0
-5.9
+1.6
+0.8
-10.5
-5.2
+2.1
+10.2
-7.2
-3.8
-10.6
+9.2
-22.2%
2017
-5.0
+4.6
+14.1
-3.8
+14.8
-22.3
+8.2
+2.8
-5.5
+9.0
+11.4
+9.6
+36.1%
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

DatePartySideQuantityPriceValue
2026-09-28ANUPAM RASAYAN INDIA LIMITED · bulkBUY22,50,000₹723.29₹162.74 Cr
2026-07-21NOVA VIDA LIMITED · bulkBUY7,00,000₹485.00₹33.95 Cr
2026-07-21NOVA VIDA LIMITED · blockBUY7,00,000₹485.00₹33.95 Cr
2026-07-21ARIAN INVESTMENT LTD · bulkSELL7,00,000₹485.00₹33.95 Cr
2026-07-21ARIAN INVESTMENT LTD · blockSELL7,00,000₹485.00₹33.95 Cr
2026-03-25HRTI PRIVATE LIMITED · bulkSELL5,81,292₹224.86₹13.07 Cr
2026-03-25HRTI PRIVATE LIMITED · bulkBUY5,17,506₹224.26₹11.61 Cr
2026-03-20RATNABALI EQUITY PRIVATE LIMITED · bulkSELL7,17,102₹212.11₹15.21 Cr

The last two years of the company's filings to the exchange, grouped by the exchange's own categories. Each opens the original document.

Read enough? Test BLISSGVS. “Buy BLISSGVS when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free